ARUP Awarded CDC Contract for Bird Flu Test Development

ARUP Laboratories has been selected as a partner by the CDC to develop a test for avian influenza A (H5N1), marking a significant collaboration in public health. This partnership includes four other laboratories: Quest Diagnostics, Labcorp, Aegis Sciences, and Ginkgo Bioworks. The initiative aims to expedite the availability of testing solutions for bird flu, allowing for proactive measures rather than reactive responses during public health emergencies. The decision comes in light of a recent case in Missouri where an individual tested positive for an H5 virus without known contact with animals, raising concerns about the virus's spread. This case is particularly notable as it represents the first instance of a human infection with H5 without a clear source. The CDC and local health authorities are currently investigating the situation, emphasizing the need for rapid testing capabilities. ARUP has been actively monitoring the bird flu situation and has engaged with the CDC for over a year to enhance its testing capabilities. The new contract formalizes this relationship, allowing ARUP to play a more integrated role in public health services. The organization is committed to expanding its testing capabilities for H5N1 and other infectious diseases, demonstrating its dedication to patient care and public health. Since 2022, there have been 15 reported human cases of bird flu in the United States, with 14 of those cases occurring since April 2023. This partnership with the CDC is a proactive step to ensure that testing solutions are readily available should the need arise, reflecting ARUP's commitment to innovation and quality in test development.